Immunoscintigraphy as potential tool in the clinical evaluation of HER2/neu targeted therapy

Current Pharmaceutical Design

Volumn 14, Issue 31, 2008, Pages 3348-3362

  Dijkers, Eli C F ^a   de Vries, Elisabeth G E ^a   Kosterink, Jos G W ^a   Brouwers, Andrienne H ^a   Lub de Hooge, Marjolijn N ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Antibodies; Diagnostic imaging; HER2 neu; Radioimmunoscintigraphy; Targeted therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN FRAGMENT; LAPATINIB; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY I 125; TRASTUZUMAB; TRASTUZUMAB GA 68; TRASTUZUMAB IN 111; TRASTUZUMAB TC 99M; TRASTUZUMAB Y 86; TRASTUZUMAB ZR 89; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT;

ANTIGEN BINDING; BINDING AFFINITY; BREAST CANCER; CANCER STAGING; CLINICAL EVALUATION; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG RESPONSE; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOSCINTIGRAPHY; INTERNALIZATION; ISOTOPE LABELING; MOLECULAR SIZE; NON INVASIVE PROCEDURE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; IMMUNOLOGY; METABOLISM; METHODOLOGY; NEOPLASM; RADIOIMMUNOASSAY; SCINTISCANNING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; RADIOIMMUNODETECTION; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2;

EID: 59649084981     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786549425     Document Type: Review

References (108)

1. Gross ME, Shazer RL, Agus DB. Targeting the HER-kinase axis in cancer. Semin Oncol 2004; 31: 9-20.
2. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994; 1198: 165-84.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
4. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12.
5. Berger MS, Locher GW, Saurer S, Gullick WJ, Waterfield MD, Groner B, et al. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 1988; 48: 1238-43.
6. Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, et al. Her-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993; 53: 4960-70.
7. Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol 1999; 112: S53-S67.
8. Oldenhuis CN, Oosting SF, Gietema JA, de Vries EG. Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer 2008; 44: 946-53.
9. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51.
10. Schaller G, Evers K, Papadopoulos S, Ebert A, Buhler H. Current use of HER2 tests. Ann Oncol 2001; 12(Suppl 1): S97-100.
11. Duffy MJ. Predictive markers in breast and other cancers: A review. Clin Chem 2005; 51: 494-503.
12. Lambros MB, Natrajan R, Reis-Filho JS. Chromogenic and fluorescent in situ hybridization in breast cancer. Hum Pathol 2007; 38: 1105-22.
13. Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 2004; 291: 1972-7.
14. McCormick SR, Lillemoe TJ, Beneke J, Schrauth J, Reinartz J. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: Comparison of HercepTest and Path-Vysion commercial assays. Am J Clin Pathol 2002; 117: 935-43.
15. Rasbridge SA, Gillett CE, Seymour AM, Patel K, Richards MA, Rubens RD, et al. The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer 1994; 70: 335-41.
16. Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005; 93: 552-6.
17. Solomayer EF, Becker S, Pergola-Becker G, Bachmann R, Kramer B, Vogel U, et al. Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients. Breast Cancer Res Treat 2006; 98: 179-84.
18. Wulfing P, Borchard J, Buerger H, Heidl S, Zanker KS, Kiesel L, et al. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res 2006; 12: 1715-20.
19. Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study. J Clin Oncol 2003; 21: 46-53.
20. Lear-Kaul KC, Yoon HR, Kleinschmidt-DeMasters BK, McGavran L, Singh M. Her-2/neu status in breast cancer metastases to the central nervous system. Arch Pathol Lab Med 2003; 127: 1451-7.
21. McCusker C. Antigen Recognition by B-cell and T-cell Receptors, Immunobiology: The immune system in health and disease - 6th edition, Janeway C Ed. Abingdon, UK, Garland Science, 2004; 103-135. 22 Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23: 1126-36.
22. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006; 6: 343-57.
23. Sheridan C. Pharma consolidates its grip on post-antibody landscape. Nat Biotechnol 2007; 25: 365-6.
24. Lendel C, Dogan J, Hard T. Structural basis for molecular recognition in an affibody: Affibody complex. J Mol Biol 2006; 359: 1293-304.
25. Orlova A, Feldwisch J, Abrahmsen L, Tolmachev V. Update: Affibody molecules for molecular imaging and therapy for cancer. Cancer Biother Radiopharm 2007; 22: 573-84.
26. Nord K, Gunneriusson E, Ringdahl J, Stahl S, Uhlen M, Nygren PA. Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat Biotechnol 1997; 15: 772-7.
27. Wu AM, Senter PD. Arming antibodies: Prospects and challenges for immunoconjugates. Nat Biotechnol 2005; 23: 1137-46.
28. Kim SJ, Park Y, Hong HJ. Antibody engineering for the development of therapeutic antibodies. Mol Cells 2005; 20: 17-29.
29. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005; 23: 1147-57.
30. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 2001; 61: 4750-5.
31. Hudson PJ, Souriau C. Engineered antibodies. Nat Med 2003; 9: 129-34
32. Bhatnagar A, Hustinx R, Alavi A. Nuclear imaging methods for non-invasive drug monitoring. Adv Drug Deliv Rev 2000; 41: 41-54.
33. van Dongen GA, Visser GW, Lub-De Hooge MN, de Vries EG, Perk LR. Immuno-PET: A navigator in monoclonal antibody development and applications. Oncologist 2007; 12: 1379-89.
34. Ruegg CL, Anderson-Berg WT, Brechbiel MW, Mirzadeh S, Gansow OA, Strand M. Improved in vivo stability and tumor targeting of bismuth-labeled antibody. Cancer Res 1990; 50: 4221-6.
35. Mirzadeh S, Brechbiel MW, Atcher RW, Gansow OA. Radiometal labeling of immunoproteins: Covalent linkage of 2-(4-isothiocyana-tobenzyl) diethylenetriaminepentaacetic acid ligands to immunoglobulin. Bioconjug Chem 1990; 1: 59-65.
36. Verel I, Visser GW, Boellaard R, Stigter-van WM, Snow GB, van Dongen GA. 89Zr immuno-PET: Comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nucl Med 2003; 44: 1271-81.
37. Ceresa BP, Schmid SL. Regulation of signal transduction by endocytosis. Curr Opin Cell Biol 2000; 12: 204-10.
38. Saga T, Endo K, Akiyama T, Sakahara H, Koizumi M, Watanabe Y, et al. Scintigraphic detection of overexpressed c-erbB-2 protooncogene products by a class-switched murine anti-c-erbB-2 protein monoclonal antibody. Cancer Res 1991; 51: 990-4.
39. Bakir MA, Eccles S, Babich JW, Aftab N, Styles J, Dean CJ, et al. c-erbB2 protein overexpression in breast cancer as a target for PET using iodine-124-labeled monoclonal antibodies. J Nucl Med 1992; 33: 2154-60.
40. Dean CJ, Eccles SA, Valeri M, Box G, Allan S, McFarlane C, et al. Rat MAbs to the product of the c-erbB-2 proto-oncogene for diagnosis and therapy in breast cancer. Cell Biophys 1993; 22: 111-27.
41. Allan SM, Dean C, Fernando I, Eccles S, Styles J, McCready VR, et al. Radioimmunolocalisation in breast cancer using the gene product of c-erbB2 as the target antigen. Br J Cancer 1993; 67: 706-12.
42. Smellie WJ, Dean CJ, Sacks NP, Zalutsky MR, Garg PK, Carnochan P, et al. Radioimmunotherapy of breast cancer xenografts with monoclonal antibody ICR12 against c-erbB2 p185: Comparison of iodogen and N-succinimidyl 4-methyl-3-(tri-n-butylstannyl) benzoate radioiodination methods. Cancer Res 1995; 55: 5842s-6s.
43. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989; 9: 1165-72.
44. Reese DM, Slamon DJ. HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells 1997; 15: 1-8.
45. De SK, Slamon D, Anderson SK, Shepard M, Fendly B, Maneval D, et al. Radiolabeled antibody targeting of the HER-2/neu oncoprotein. Cancer Res 1992; 52: 1916-23.
46. Tsai SW, Sun Y, Williams LE, Raubitschek AA, Wu AM, Shively JE. Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5. Bioconjug Chem 2000; 11: 327-34.
47. Milenic DE, Garmestani K, Brady ED, Albert PS, Ma D, Abdulla A, et al. Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. Clin Cancer Res 2004; 10: 7834-41.
48. Garmestani K, Milenic DE, Plascjak PS, Brechbiel MW. A new and convenient method for purification of 86Y using a Sr(II) selective resin and comparison of biodistribution of 86Y and 111In labeled Herceptin. Nucl Med Biol 2002; 29: 599-606.
49. Lub-De Hooge MN, Kosterink JG, Perik PJ, Nijnuis H, Tran L, Bart J, et al. Preclinical characterisation of 111In-DTPA-trastuzumab. Br J Pharmacol 2004; 143: 99-106.
50. 89Zr-trastuzumab for clinical HER2 immunoPET imaging. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings 2007; 25: Abstract # 3508.
51. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004; 22: 701-6.
52. Smith-Jones PM, Solit D, Afroze F, Rosen N, Larson SM. Early tumor response to Hsp90 therapy using HER2 PET: Comparison with 18F-FDG PET. J Nucl Med 2006; 47: 793-6.
53. Tang Y, Wang J, Scollard DA, Mondal H, Holloway C, Kahn HJ, et al. Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using (111)In-trastuzumab (Herceptin) Fab fragments. Nucl Med Biol 2005; 32: 51-8.
54. Tang Y, Scollard D, Chen P, Wang J, Holloway C, Reilly RM. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments. Nucl Med Commun 2005; 26: 427-32.
55. Olafsen T, Tan GJ, Cheung CW, Yazaki PJ, Park JM, Shively JE, et al. Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. Protein Eng Des Sel 2004; 17: 315-23.
56. Olafsen T, Kenanova VE, Sundaresan G, Anderson AL, Crow D, Yazaki PJ, et al. Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res 2005; 65: 5907-16.
57. Crews JR, Maier LA, Yu YH, Hester S, O'Briant K, Leslie DS, et al. A combination of two immunotoxins exerts synergistic cytotoxic activity against human breast-cancer cell lines. Int J Cancer 1992; 51: 772-9
58. Adams GP, McCartney JE, Tai MS, Oppermann H, Huston JS, Stafford WF, III, et al. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res 1993; 53: 4026-34.
59. Huston JS, Adams GP, McCartney JE, Tai MS, Hudziak RM, Oppermann H, et al. Tumor targeting in a murine tumor xenograft model with the (sFv')2 divalent form of anti-c-erbB-2 single-chain Fv. Cell Biophys 1994; 24-25: 267-78.
60. Adams GP, Tai MS, McCartney JE, Marks JD, Stafford WF, III, Houston LL, et al. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res 2006; 12: 1599-605.
61. Adams GP, McCartney JE, Wolf EJ, Eisenberg J, Tai MS, Huston JS, et al. Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 anti-c-erbB-2 single-chain Fv: Effects of dose escalation and repeated i.v. administration. Cancer Immunol Immunother 1995; 40: 299-306.
62. Khawli LA, Kassis AI. Synthesis of 125I labeled N-succinimidyl piodobenzoate for use in radiolabeling antibodies. Int J Rad Appl Instrum B 1989; 16: 727-33.
63. Adams GP, McCartney JE, Wolf EJ, Eisenberg J, Huston JS, Bookman MA, et al. Enhanced tumor specificity of 741F8-1 (sFv')2, an anti-c-erbB-2 single-chain Fv dimer, mediated by stable radioiodine conjugation. J Nucl Med 1995; 36: 2276-81.
64. Schier R, Marks JD, Wolf EJ, Apell G, Wong C, McCartney JE, et al. In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. Immunotechnology 1995; 1: 73-81.
65. Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD, et al. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res 1998; 58: 485-90.
66. Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM, et al. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer 1998; 77: 1405-12.
67. Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, et al. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res 2005; 65: 1471-8.
68. Gonzalez Trotter DE, Manjeshwar RM, Doss M, Shaller C, Robinson MK, Tandon R, et al. Quantitation of small-animal (124)I activity distributions using a clinical PET/CT scanner. J Nucl Med 2004; 45: 1237-44.
69. Steffen AC, Orlova A, Wikman M, Nilsson FY, Stahl S, Adams GP, et al. Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. Eur J Nucl Med Mol Imaging 2006; 33: 631-8.
70. Mume E, Orlova A, Larsson B, Nilsson AS, Nilsson FY, Sjoberg S, et al. Evaluation of ((4-hydroxyphenyl)ethyl)maleimide for sitespecific radiobromination of anti-HER2 affibody. Bioconjug Chem 2005; 16: 1547-55.
71. Orlova A, Nilsson FY, Wikman M, Widstrom C, Stahl S, Carlsson J, et al. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. J Nucl Med 2006; 47: 512-9.
72. Orlova A, Magnusson M, Eriksson TL, Nilsson M, Larsson B, Hoiden-Guthenberg I, et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 2006; 66: 4339-48
73. Tran T, Orlova A, Sivaev I, Sandstrom M, Tolmachev V. Comparison of benzoate- and dodecaborate-based linkers for attachment of radioiodine to HER2-targeting affibody ligand. Int J Mol Med 2007; 19: 485-93.
74. Tolmachev V, Nilsson FY, Widstrom C, Andersson K, Rosik D, Gedda L, et al. 111In-benzyl-DTPA-ZHER2: 342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med 2006; 47: 846-53.
75. -DTPA-Z(HER2: 342), an affibody ligand coniugate for targeting of HER2-expressing malignant tumors. Q J Nucl Med Mol Imaging 2007; 51: 314-23.
76. Orlova A, Tran T, Widstrom C, Engfeldt T, Eriksson KA, Tolmachev V. Pre-clinical evaluation of [111In]-benzyl-DOTAZ(HER2: 342), a potential agent for imaging of HER2 expression in malignant tumors. Int J Mol Med 2007; 20: 397-404.
77. Orlova A, Tolmachev V, Pehrson R, Lindborg M, Tran T, Sandstrom M, et al. Synthetic affibody molecules: A novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res 2007; 67: 2178-86.
78. Tran T, Engfeldt T, Orlova A, Widstrom C, Bruskin A, Tolmachev V, et al. In vivo evaluation of cysteine-based chelators for attachment of 99mTc to tumor-targeting affibody molecules. Bioconjug Chem 2007; 18: 549-58.
79. Engfeldt T, Orlova A, Tran T, Bruskin A, Widstrom C, Karlstrom AE, et al. Imaging of HER2-expressing tumours using a synthetic affibody molecule containing the 99mTc-chelating mercaptoacetylglycyl-glycyl-glycyl (MAG3) sequence. Eur J Nucl Med Mol Imaging 2007; 34: 722-33.
80. Engfeldt T, Tran T, Orlova A, Widstrom C, Feldwisch J, Abrahmsen L, et al. (99m)Tc-chelator engineering to improve tumour targeting properties of a HER2-specific affibody molecule. Eur J Nucl Med Mol Imaging 2007; 34: 1843-53.
81. Tran T, Engfeldt T, Orlova A, Sandstrom M, Feldwisch J, Abrahmsen L, et al. (99m)Tc-maEEE-Z(HER2: 342), an affibody molecule-based tracer for the detection of HER2 expression in malignant tumors. Bioconjug Chem 2007; 18: 1956-64.
82. de Korte MA, de Vries EG, Lub-De Hooge MN, Jager PL, Gietema JA, van der Graaf WT, et al. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer 2007; 43: 2046-51.
83. Behr TM, Behe M, Wormann B. Trastuzumab and breast cancer. N Engl J Med 2001; 345: 995-6.
84. Perik PJ, Lub-De Hooge MN, Gietema JA, van der Graaf WT, de Korte MA, Jonkman S, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2006; 24: 2276-82.
85. Borjesson PK, Jauw YW, Boellaard R, de BR, Comans EF, Roos JC, et al. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res 2006; 12: 2133-40.
86. Wong JY, Chu DZ, Williams LE, Yamauchi DM, Ikle DN, Kwok CS, et al. Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer. Clin Cancer Res 2004; 10: 5014-21.
87. Willkomm P, Bender H, Bangard M, Decker P, Grunwald F, Biersack HJ. FDG PET and immunoscintigraphy with 99mTc-labeled antibody fragments for detection of the recurrence of colorectal carcinoma. J Nucl Med 2000; 41: 1657-63.
88. Goldenberg DM, Wlodkowski TJ, Sharkey RM, Silberstein EB, Serafini AN, Garty II, et al. Colorectal cancer imaging with iodine-123-labeled CEA monoclonal antibody fragments. J Nucl Med 1993; 34: 61-70.
89. Shields AF. Positron emission tomography measurement of tumor metabolism and growth: Its expanding role in oncology. Mol Imaging Biol 2006; 8: 141-50.
90. Lawrence S. Billion dollar babies--biotech drugs as blockbusters. Nat Biotechnol 2007; 25: 380-2.
91. Berenson A. A cancer drug shows promise, at a price that many can't pay. NY Times 2006; A1, C2.
92. Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med 2005; 35: 84-99.
93. El-Deiry WS, Sigman CC, Kelloff GJ. Imaging and oncologic drug development. J Clin Oncol 2006; 24: 3261-73.
94. Hodgson NC, Gulenchyn KY. Is there a role for positron emission tomography in breast cancer staging? J Clin Oncol 2008; 26: 712-20.
95. Li L, Yazaki PJ, Anderson AL, Crow D, Colcher D, Wu AM, et al. Improved biodistribution and radioimmunoimaging with poly (ethylene glycol)-DOTA-conjugated anti-CEA diabody. Bioconjug Chem 2006; 17: 68-76.
96. Wen X, Wu QP, Ke S, Ellis L, Charnsangavej C, Delpassand AS, et al. Conjugation with (111)In-DTPA-poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225. J Nucl Med 2001; 42: 1530-7.
97. Dennis MS, Jin H, Dugger D, Yang R, McFarland L, Ogasawara A, et al. Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res 2007; 67: 254-61.
98. Tolmachev V, Orlova A, Pehrson R, Galli J, Baastrup B, Andersson K, et al. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res 2007; 67: 2773-82.
99. Sharkey RM, Karacay H, McBride WJ, Rossi EA, Chang CH, Goldenberg DM. Bispecific antibody pretargeting of radionuclides for immuno single-photon emission computed tomography and immuno positron emission tomography molecular imaging: An update. Clin Cancer Res 2007; 13: 5577s-85s.
100. Eccles SA, Court WJ, Box GA, Dean CJ, Melton RG, Springer CJ. Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185. Cancer Res 1994; 54: 5171-7.
101. Zalutsky MR, Xu FJ, Yu Y, Foulon CF, Zhao XG, Slade SK, et al. Radioiodinated antibody targeting of the HER-2/neu oncoprotein: Effects of labeling method on cellular processing and tissue distribution. Nucl Med Biol 1999; 26: 781-90.
102. Wiercioch R, Balcerczak E, Byszewska E, Mirowski M. Uptake of radiolabelled herceptin by experimental mammary adenocarcinoma. Nucl Med Rev Cent East Eur 2003; 6: 99-103.
103. Costantini DL, Chan C, Cai Z, Vallis KA, Reilly RM. (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): An Auger electron-emitting radiotherapeutic agent for HER2/ neu-amplified breast cancer. J Nucl Med 2007; 48: 1357-68.
104. Sampath L, Kwon S, Ke S, Wang W, Schiff R, Mawad ME, et al. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. J Nucl Med 2007; 48: 1501-10.
105. Tai MS, McCartney JE, Adams GP, Jin D, Hudziak RM, Oppermann H, et al. Targeting c-erbB-2 expressing tumors using single-chain Fv monomers and dimers. Cancer Res 1995; 55: 5983s-9s.
106. Chakravarty R, Pandey U, Manolkar RB, Dash A, Venkatesh M, Pillai MR. Development of an electrochemical 90 Sr-90 Y generator for separation of 90 Y suitable for targeted therapy. Nucl Med Biol 2008; 35(2): 245-53.
107. Feun L, You M, Wu CJ, Kuo MT, Wangpaichitr M, Spector S, et al. Arginine deprivation as a targeted therapy for cancer. Curr Pharm Des 2008; 14(11): 1049-57.
108. Landini L, Santarelli MF, Landini L Jr, Positano V. Fundamentals in cardiovascular imaging technologies. Curr Pharm Des 2008; 14(18): 1745-52.